Senores Pharmaceuticals Limited has informed the Exchange about Investor Presentation
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals filed its Q1FY26 investor presentation showing strong revenue growth of 72% year-on-year to Rs. 138 Crs, driven by the Regulated Markets segment which contributed 65% of revenue at Rs. 90.1 Crs. EBITDA rose 60% YoY to Rs. 34.2 Crs with margin at 24.8%, while PAT jumped 95% YoY to Rs. 21.2 Crs. The company reported positive operating cash flow of Rs. 11 Crs and increased its stake in subsidiary Havix to 73%, with plans to raise it to 78%. Branded Generics business grew around 4.5x YoY, and the company added 5 new CDMO/CMO products during the quarter. Management highlighted expansion plans including a 3rd OSD manufacturing line by Q3FY26 and a new API greenfield plant, while noting insulation from US tariff concerns due to local US manufacturing.
Strong quarterly performance with broad-based growth across segments is positive for the stock, though EBITDA margin contraction of 170 bps YoY remains a watch point. Robust product pipeline and capacity expansion plans signal sustained growth momentum ahead.